Lateral Pharma Appoint New Director: Colin Hannah

Colin Hannah


Colin Hannah Photo


Lateral Pharma is pleased to announce the appointment of a new director, Colin Hannah. He has over 30 years of extensive high level corporate and commercial experience leading the operations of a number of Global Healthcare Corporations based in Australia, New Zealand and the United Kingdom. Colin is ideally placed to drive the development and application of the firm’s unique approach and capabilities in this sector. Having built his leadership skills off a highly successful business development and sales and marketing career he has consistantly delivered “best in class” performance from a local and Global perspective across all major therapeutic sectors, notably Oncology, Cardiology, Diabetes, Allergy, Mental Health and Rheumatology and through all customer channels be it Grocery, OTC, and primary or secondary care. He has been a key member of many Global Task Forces around Global Product Launches and Commercial Initiatives and has led organisations through periods of major challenges, restructures and change. Prior to being expatriated to Australia in 2002, he led several initiatives that resulted in Industry recognition winning peer reviewed “Brand Revitalisation” awards and built an organisation that achieved the most successful product launch in UK Pharmaceutical history. On arrival in Australia as the MD for Aventis, he restructured commercial operations and became the fastest growing organisation in the top ten Pharmaceutical companies despite having no new product launches. Appointed at the sanofi aventis merger, he led the integration, change management process and relocation of the business. He returned to the UK to head up Innovex UK, part of Quintiles Transnational, the leading healthcare services outsourcing specialists before being appointed Vice President Commercial Operations Australia/New Zealand for Hospira, the world leading injectible pharmaceutical supplier. Colin has served as a board member for all the major Industry associations, (Medicines Australia, GMIA-Generic Medicines Industry Association and the MTAA-Medical Technology Association of Australia) and as a member of peak Industry/Government bodies. In more recent times, Colin joined nem Australasia a boutique business advisory firm, to set up their Pharmaceutical and Healthcare division. nem was founded in Australia in 2001 by three former senior corporate executives who saw an opportunity to assist a wide range of organisations achieve their business objectives far more quickly than they could achieve with their own resources. As a partner at nem, he relishes the opportunity to leverage his experience and work with people, teams and organisations to realise their aspirations.